PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
Jiwon Oh, MD, PhD, FRCPC - Moving Toward the Future in MS Management: What's the Latest on BTK Inhibition?
Go online to PeerView.com/WGE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Bruton tyrosine kinase (BTK) inhibitors may soon augment the current armamentarium of DMTs for MS. Four BTK inhibitors are currently in phase 3 trials, generating great interest due to their capacity to reach therapeutic concentrations in the central nervous system and ability to affect processes mediated by B cells and microglia that contribute to the inflammatory and neurodegenerative processes that drive MS. In this activity, an expert reviews the rationale for and shares the latest findings on the efficacy, safety, and tolerability of this promising line of treatment. Upon completion of this activity, participants should be better able to: Explain the rationale for inhibiting BTK to treat MS; Evaluate the current evidence regarding the efficacy, safety, and tolerability of BTK inhibitors being studied for the treatment of MS; and Identify patients who may benefit by treatment with BTK inhibitors, based on current evidence and individual treatment needs and priorities.
Erik P. Sulman, MD, PhD - Harnessing Novel Synergies With Tumor Treating Fields: Insights on Improving Survival With Multimodal Care in Aggressive Tumors
Go online to PeerView.com/DSK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. For over a century, surgery, radiotherapy, and systemic therapy have served as the mainstays of cancer treatment. An opportunity to further improve survival and quality of life for patients with aggressive solid tumors has emerged with novel locoregional therapies (LRTs)—in particular, tumor treating fields (TTFields)—a state-of-the-art, noninvasive modality associated with clear efficacy benefits and minimal toxicity. Currently, TTFields is approved for newly diagnosed and recurrent glioblastoma (GBM) and resectable, previously untreated malignant pleural mesothelioma (MPM) and is being further examined across a range of solid tumors with poor prognoses. In a new activity from PeerView, expert panelists use a mix of case-based instruction and high-level presentations of evidence and guidelines to illustrate the effective use of TTFields in the treatment of patients with GBM and MPM. Throughout, the expert panelists share insights on engaging, real-world patient cases and perspectives on using TTFields as a component of multimodal therapy. Key topics include patient selection for therapy, safety management, provision of patient and caregiver education, and the potential future of TTFields as a unique LRT option in liver, pancreatic, ovarian, and gastric cancers. Upon completion of this activity, participants should be better able to: Cite the mechanistic rationale and clinical evidence on use of novel locoregional therapies (LRTs), such as tumor treating fields (TTFields), in the treatment of patients with glioblastoma multiforme (GBM) or malignant pleural mesothelioma (MPM); Assess recent clinical trial evidence on emerging multimodal strategies incorporating TTFields across various solid tumor malignancies, including thoracic, abdominal, and gynecologic cancers; Incorporate TTFields into multimodal treatment plans, including in the context of clinical trials, for appropriately selected patients with GBM, MPM, and other solid tumors; and Employ evidence- and team-based strategies to mitigate and manage AEs associated with novel LRTs (eg, TTFields) in patients with solid tumors.
Sandeep K. Gupta, MD - Updates in Eosinophilic Esophagitis: Exploring Underlying Mechanisms and Integrating Novel Targeted Therapy to Improve Patient Care
Go online to PeerView.com/MKN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Eosinophilic esophagitis (EoE) is an increasingly prevalent, chronic, T2 inflammatory disease triggered by food and/or environmental allergens. Due to underlying tissue inflammation, patients suffer diminished quality of life due to symptoms such as weight loss, difficulty swallowing, and heartburn. Patients can experience these symptoms for a long time before receiving a proper diagnosis. Once diagnosed, treatment options have historically been limited. Fortunately, therapies that treat other type 2 disorders are in development or are approved to treat EoE. At a recent live event, experts used patient cases to discuss the diagnosis, underlying causes, and the newest treatments for EoE, including biologic therapies. Watch this on-demand version now! Upon completion of this activity, participants should be better able to: Distinguish signs and symptoms of eosinophilic esophagitis (EoE) among children and adults to enable an earlier diagnosis and minimize complications due to uncontrolled disease; Recognize underlying mechanisms of EoE, including the role of key cytokines such as interleukins -4, -13, and -5 as drivers of type 2 inflammation and how this relates to emerging treatment; and Apply the latest expert recommendations and clinical evidence to the treatment of patients with EoE, particularly as novel and emerging agents become available.
R. Scott Wright, MD - Diagnosing and Treating Hyperlipidemia in Family Medicine: Exploring the Latest Clinical Evidence and the Role of Novel PCSK9-Targeting Therapies
Go online to PeerView.com/QCN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on hyperlipidemia discusses evidence-based strategies for diagnosing and individualizing treatment plans with PCSK9-targeting agents to improve patient outcomes. Upon completion of this activity, participants should be better able to: Perform a diagnostic evaluation based on current clinical guidelines for the treatment of hyperlipidemia; Assess the mechanisms of action, efficacy, and safety of PCSK9-targeting agents designed to further reduce lipid levels in patients with hyperlipidemia; Identify patients who may benefit from treatment with PCSK9-targeting therapies; and Recognize the role of multidisciplinary collaboration and patient education to optimize outcomes in patients with hyperlipidemia.
Alicia K. Morgans, MD, MPH - Creating a Roadmap for Modern Prostate Cancer Treatment: How to Use the Most Recent Evidence on Novel Therapeutic Strategies and Shared Decision-Making to Personalize Patient Care
Go online to PeerView.com/XGS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Two experts highlight how a prostate cancer care team can use the latest clinical evidence, treatment guidelines, and consensus recommendations to improve outcomes for patients with prostate cancer and will give practical insights on applying next-generation anti-androgen agents, PARP inhibitors, and chemotherapy to the prostate cancer treatment landscape. By providing a “roadmap” to the multiple pathways of prostate cancer management, this program serves as a resource for professionals interested in the present and future applications of new science in patient care. Upon completion of this activity, participants should be better able to: Review current guideline recommendations related to germline and somatic tumor testing in patients with prostate cancer; Select patients with advanced prostate cancer who are likely to benefit from novel systemic therapies and combination strategies based on recent clinical evidence, regulatory updates, genetic/molecular status, and current practice guidelines; and Implement personalized treatment plans for patients with advanced prostate cancer that incorporate new agents and combinations, expert recommendations, shared decision- making, and multidisciplinary team-based care.
Nasser Altorki, MD - Extending Survival and Setting Our Sights on Cure in Resectable NSCLC: Getting the Details of Perioperative Immunotherapy Right
Go online to PeerView.com/CDB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Research and clinical practice continue to build on the success achieved to date with cancer immunotherapy and to refine rational strategies to expand its benefits to more patients, including in curative-intent settings. Immunotherapy has started to radically transform the multimodal approach to treatment of resectable stage I-III NSCLC. Recently, highly positive data have emerged from the first few phase 3 trials evaluating neoadjuvant and adjuvant immunotherapies in resectable lung cancer, leading to regulatory approvals and new standards of care in these settings. What do these advances mean for thoracic surgeons, medical oncologists, pulmonologists, and other multidisciplinary specialists, and what changes in practice are needed? What challenges and unanswered questions remain? This PeerView educational activity, based on a recent live symposium, brings together top experts to discuss new, practice-changing evidence, the implications and applicability of the latest data to practice, and how to achieve better partnerships across disciplines to facilitate the incorporation of immunotherapies into new standards of care to improve outcomes and quality of life for patients with stage I-III NSCLC. Upon completion of this activity, participants should be better able to: Discuss the mechanistic and biologic rationale for using immunotherapy as a component of multimodal therapy in early-stage lung cancer and key clinical trials evaluating immunotherapies in these settings; Summarize the latest findings on surrogate endpoints, such as pathologic response criteria, to assess treatment response and evaluate the prognosis of patients with resectable lung cancer who are receiving immunotherapy; Identify patients with resectable NSCLC who are eligible for perioperative immunotherapy, considering the benefits/limitations and surgical implications based on an understanding of the latest evidence and persisting misperceptions; and Collaborate with the multidisciplinary team to integrate immunotherapy into individualized, multimodal treatment plans for eligible patients with stage I-III resectable NSCLC.
Your titles are so long I can't see what the podcast is about without playing it and watching the long title scroll along my screen. That makes your podcasts too difficult to access to be useful.